

Aurinia Pharmaceuticals Inc. closes US\$173.1M public offering

Date closed: 3/20/2017

Value: US\$173.1 million

On March 20, 2017, Aurinia Pharmaceuticals Inc. (Aurinia) completed its underwritten public offering of 25,645,000 common shares, including 3,345,000 common shares pursuant to the full exercise of the underwriters' option to purchase additional common shares (the Offering). The common shares were sold at a public offering price of US\$6.75 per share. The gross proceeds to Aurinia from the Offering were approximately US\$173.1 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The Offering may be the largest biotech follow on financing ever conducted by a Canadian company.

Leerink Partners LLC and Cantor Fitzgerald & Co. acted as joint book-running managers for the Offering.

Aurinia, headquartered in Victoria, British Columbia, is a clinical stage biopharmaceutical company focused on the global immunology market.

BLG represented Aurinia with a team led by [Stephen P. Robertson](#) that included [Kent Kufeldt](#) and [Michelle Wilkinson](#).

For more information, please contact:

Tamara Costa

National Director, Marketing and Communications
Borden Ladner Gervais LLP
TCosta@blg.com
416.350.2642



BLG | Canada's Law Firm

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 725 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

[blg.com](https://www.blg.com)

© 2025 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.